BioSpace News Archive

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of the first patient in its pivotal Phase 3 COVID-19 trial in Brazil for patients with severe symptoms.

Algernon Pharmaceuticals Inc. is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote Presentation at the Microdose Virtual 2021 “The DMT Conference: A Molecular Masterclass”. The conference will be taking place on September 9th and 10th

Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc.

PharmaForce International (PFI) recently completed a study that benchmarks the leading Oncology/Hematology/Immuno-Oncology sales and marketing organizations in five major European countries.

Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid cancer cells for disruption”, which was issued by the US Patent and Trademark Office (USPTO) on August 31.

Eli Lilly and Company announced the pricing of its first sustainability bond to advance its global environmental, social and governance strategy to increase access to medicines, improve lives and communities, empower a diverse workforce, minimize environmental impact and operate ethically and responsibly.

Olympus announced the launch of the first devices in the new POWERSEAL™ family of advanced bipolar surgical energy products.

You’ve been in a car accident and sustained a head injury. You recovered, but years later you begin having difficulty sleeping. You also become very sensitive to noise and bright lights, and find it hard to carry out your daily activities, or perform well at your job.

The outcomes of this research may revolutionize a breakthrough of the current limitations in gene editing nuclease delivery techniques.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will participate in the following conferences in the month of September/